Bevacizumab in patients with previously treated metastatic colorectal cancer: preliminary results of a phase II study (bevacolor)

被引：0
|
作者：
Borg, C. [1 ]
Delord, J. P. [2 ]
Husseini, F. [3 ]
Lenoir, V. Trillet [4 ]
Faroux, R.
Francois, E. [5 ]
Ychou, M. [6 ]
Bergougnoux, L. [7 ]
Bennouna, J. [8 ]
Douillard, J. Y. [8 ]
机构：
[1] CHU Besancon, INSERM, U 645, Toulouse, France
[2] Inst Claudius Regaud, Toulouse, France
[3] Hop Louis Pasteur, Colmar, France
[4] Ctr Hosp Lyon Sud, Lyon, France
[5] Ctr Antoine Lacassagne, F-06054 Nice, France
[6] CHRU, Montpellier, France
[7] Dept Stat, Neuilly sur Seine, France
[8] Ctr Rene Gauducheau, F-44035 Nantes, France
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)70998-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3070
引用
收藏
页码：257 / 257
页数：1
相关论文
共 50 条
  • [21] A phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): Final PFS results
    Cunningham, D.
    Wong, R. P.
    D'haens, G.
    Douillard, J.
    Robertson, J.
    Saunders, O.
    Stone, M.
    Van Cutsem, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [22] Phase II study of Regorafenib as single agent for the treatment of patients with metastatic colorectal cancer with any RAS or BRAF mutation and previously treated with FOLFOXIRI plus bevacizumab
    Garcia Alfonso, P.
    Ortiz, M. J.
    Duran, G.
    Falco, E.
    Munoz, A.
    Garcia-Paredes, B.
    Salgado, M.
    Lopez-Ladron, A.
    Vieitez de Prado, J. M.
    Valladares, M.
    Salud, A.
    Guillen-Ponce, C.
    Lopez, R.
    Robles, L.
    Juarez, A.
    Serrano, S.
    Montagut, C.
    Zanui, M.
    Gil Raga, M.
    La Casta, A.
    Benavides, M.
    Aranda, E.
    ANNALS OF ONCOLOGY, 2015, 26
  • [23] Phase II results of tasisulam-sodium in previously treated patients with metastatic breast cancer
    Schwartzberg, Lee Steven
    Soliman, Hatem Hussein
    Conlin, Alison Katherine
    Ruud, Christopher O.
    Tezcan, Haluk
    Bromund, Jane
    Hogeterp, Kevin
    Kaiser, Christopher
    Chen, Jian
    Chow, Kay
    Ilaria, Robert L.
    Miller, Kathy
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [24] Phase Ib study of dulanermin combined with FOLFIRI (with or without bevacizumab [BV]) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC)
    Kasubhai, Saifuddin M.
    Bendell, Johanna C.
    Kozloff, Mark
    Kapp, Amy V.
    Ashkenazi, Avi
    Royer-Joo, Stephanie
    Portera, Chia C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [25] Multicenter Phase II Study of Everolimus in Patients With Previously Treated Metastatic Gastric Cancer
    Doi, Toshihiko
    Muro, Kei
    Boku, Narikazu
    Yamada, Yasuhide
    Nishina, Tomohiro
    Takiuchi, Hiroya
    Komatsu, Yoshito
    Hamamoto, Yasuo
    Ohno, Nobutsugu
    Fujita, Yoshie
    Robson, Matthew
    Ohtsu, Atsushi
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (11) : 1904 - 1910
  • [26] A Phase II Study of Bevacizumab, Oxaliplatin, and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer A Prospective, Multicenter Trial of the Korean Cancer Study Group
    Hong, Yong Sang
    Lee, Sung Sook
    Kim, Kyu-pyo
    Lee, Jae-Lyun
    Kang, Yoon-Koo
    Shin, Sang Joon
    Ahn, Joong Bae
    Jung, Kyung Hae
    Im, Seock-Ah
    Kim, Tae-You
    Kim, Jee Hyun
    Park, Young Suk
    Kim, Tae Won
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2014, 37 (01): : 19 - 23
  • [27] Pemetrexed for previously treated patients with metastatic gastric cancer: a prospective phase II study
    Zhang, D. S.
    Jin, Y.
    Luo, H. Y.
    Wang, Z. Q.
    Qiu, M. Z.
    Wang, F. H.
    Li, Y. H.
    Xu, R. H.
    BRITISH JOURNAL OF CANCER, 2015, 112 (02) : 266 - 270
  • [28] Pemetrexed for previously treated patients with metastatic gastric cancer: a prospective phase II study
    D S Zhang
    Y Jin
    H Y Luo
    Z Q Wang
    M Z Qiu
    F H Wang
    Y H Li
    R H Xu
    British Journal of Cancer, 2015, 112 : 266 - 270
  • [29] Final phase II trial results of Sorafenib plus Capecitabine (SorCape) in previously treated metastatic colorectal cancer
    George, Thomas J.
    Ivey, Alison Marguerite
    Daily, Karen Colleen
    Dang, Long H.
    Watson, Scott
    McEwan, Margaret A.
    Lu, Xiaomin
    Tan, Sanda
    Iqbal, Atif
    Duff, Jennifer Michelle
    Allegra, Carmen Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] FOLFOXIRI plus bevacizumab (BEV) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): Preliminary safety results from the OPAL study
    Stein, Alexander
    Atanackovic, Djordje
    Hildebrandt, Bert
    Stuebs, Patrick
    Steffens, Claus-Christoph
    Brugger, Wolfram
    Hapke, Gunnar
    Illerhaus, Gerald
    Bluemner, Ernst
    Bokemeyer, Carsten
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
12345